Meeting
2020 ASCO Virtual Scientific Program
Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: A multicenter phase II study.
Authors
Shin-Ichi Miyatake
Osaka Medical College, Takatsuki, Japan
Shin-Ichi Miyatake , Shinji Kawabata , Hiromi Goto , Yoshitaka Narita , Minoru Suzuki , Katsumi Hirose , Yoshihiro Takai , Koji Ono , Takanori Ohnishi , Hiroki Tanaka , Takahiro Kato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
JapicCTI-194742
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2536)
DOI
10.1200/JCO.2020.38.15_suppl.2536
Abstract #
2536
Poster Bd #
27
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).
First Author: Annick Desjardins
Poster
2016 ASCO Annual Meeting
PSMA ADC for progressive glioblastoma: Phase II Brown University Oncology Research Group Study.
First Author: Heinrich Elinzano
Poster
2016 ASCO Annual Meeting
Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.
First Author: Francois M. Lebel
Poster
2015 ASCO Annual Meeting
Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102).
First Author: Vinay K. Puduvalli